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Abstract
Background: This retrospective analysis reports on the comparative outcome of acute gastrointestinal (GI) and
genitourinary (GU) toxicities between conformal radiation therapy (CRT) and intensity modulated radiation therapy
(IMRT) techniques in the treatment of patients with pelvic tumors.
Methods: From January 2002 to December 2008, 69 patients with pelvic tumors underwent whole pelvic CRT and
65 underwent whole pelvic IMRT to treat pelvic lymph nodes and primary tumor regions. Total dose to the whole
pelvis ranged from 50 to 50.4 Gy in 25 to 28 daily fractions. Chemotherapy (CT) regimen, when employed, was
based upon primary tumor. Acute GI and GU toxicities were graded by RTOG/EORTC acute radiation morbidity
criteria.
Results: Absence of GI symptoms during radiotherapy (grade 0) was more frequently observed in the IMRT group
(43.1% versus 8.7; p < 0.001) and medication for diarrhea (Grade 2) was more frequently used in the CRT group
(65.2% versus 38.5%; p = 0.002). Acute GI grade 1 and 3 side effects incidence was similar in both groups (18.5%
versus 18.8%; p = 0.95 and 0% versus 7.2%; p = 0.058, respectively). Incidence of GU toxicity was similar in both
groups (grade 0: 61.5% versus 66.6%, p = 0.54; grade 1: 20% versus 8.7%, p = 0.06; grade 2: 18.5% versus 23.5%, p =
0.50 and grade 3: 0% versus 1.5%, p > 0.99).
Conclusions: This comparative case series shows less grade 2 acute GI toxicity in patients treated with whole
pelvic IMRT in comparison with those treated with CRT. Incidence of acute GU toxicity was similar in both groups.
Background
Radiation therapy (RT) plays an important role in the
treatment of malignant pelvic tumors, such as endome-
trial, cervical, rectal, vesical, and anal cancers. The use
of the Intensity Modulated Radiation Therapy (IMRT)
for treatment of these tumors has increased in the last
years due to its capacity to decrease the amount of
radiation dose delivered to the adjacent normal tissues,
such as small bowel, bladder, rectum and bone marrow.
Therefore, an advantage of this technique may be a
potential benefit to decrease acute and late toxicities.
Gastrointestinal (GI) complications are among the
most common undesirable side effects for patients trea-
ted with whole pelvic RT [1-3]. Diarrhea, a very frequent
symptom, is not only uncomfortable but can also cause
dehydration and nutrients malabsorption [4]. Genitour-
inary (GU) and hematologicals i d ee f f e c t sa r ea l s or e l e -
vant toxicities in the treatment of whole pelvis with RT.
Several dosimetric studies have already shown signifi-
cant reduction of radiation dose delivered to the small
bowel, bladder, rectum, bone marrow and others
organs-at-risk (OAR) with the use of IMRT rather than
conventional or conformal radiotherapy (CRT) [5-15].
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tial to reduce both acute and chronic RT toxicities. Pub-
lished clinical outcomes with pelvic IMRT report
reduced GI, GU and hematological toxicities when com-
pared with conventional or CRT techniques but most of
these studies are comparative case series or retrospective
analyses with a small number of patients or with consid-
erable heterogeneity [16-25].
This retrospective and comparative case series aimed
to report results of acute GI and GU toxicities in
patients with pelvic tumors treated with CRT versus
I M R Tt e c h n i q u e s .T h i si st h ef i r s tc l i n i c a lr e p o r to n
IMRT from South America. All other series are from
United States of America (USA) and Europe.
Methods
Patients
We retrospectively compared 69 patients with pelvic
tumors treated by whole pelvic CRT with 65 treated by
whole pelvic IMRT, to evaluate the incidence and sever-
ity of acute GI and GU toxicities during the treatment.
No patient had any symptom or morbidity before the
RT treatment. Patients from both groups were treated
between January 2002 and December 2008 in the
Department of Radiation Oncology at the Hospital
Israelita Albert Einstein, in São Paulo. Primary tumor
sites included endometrium, cervix, rectum and anal
canal in the CRT group and endometrium, cervix,
rectum, anal canal and bladder in the IMRT group.
Table 1 summarizes patients’ characteristics of both
groups.
Radiotherapy
Patients from both groups were treated by whole pelvic
RT following the International Commission on Radia-
tion Units and Measurements (ICRU) No. 50 recom-
mendations [26]. The clinical target volume (CTV) was
defined as pelvic lymph nodes and primary tumor
region and was contoured on individual axial CT slices.
The lymph node regions were determined by encom-
passing the blood vessels with a 2 cm margin and based
upon primary tumor site. The planning target volume
(PTV) was created expanding the CTV by 1 cm. The
small bowel region was defined by contouring the peri-
toneal cavity from the L4 level and excluding the rec-
tum, bladder and blood vessels. The dose prescribed, to
encompass at least 95% of the PTV, ranged from 45 to
50.4 Gy, delivered in 25 to 28 daily fractions in the
phase of elective pelvic lymph node treatment. Treat-
ment plannings were generated using the Eclipse Helios
software (Varian Medical Systems, Palo Alto, CA) for
CRT and IMRT. Dose volume restrictions used for
OARs in both groups are described in Table 2.
In the CRT group, plans were based on 3 or 4 pelvic
isocentric conformed coplanar fields with energy of 18-
MV and patients were treated with a Varian CL2100 C
linear accelerator (Varian Medical Systems, Palo Alto,
CA) equipped with 80-leaf multileaf collimator, while in
the IMRT group, treatment plannings were based upon
a dynamic technique ("sliding window”), using 5 to 9
isocentric coplanar fields, equally spaced, with energy of
15-MV and patients were treated with Varian CL2300
EX linear accelerator (Varian Medical Systems, Palo
Alto, CA) equipped with 120-leaf multileaf collimator.
Chemotherapy
Chemotherapy (CT), when employed, was based on pri-
mary tumor site. In both groups, the proportion of
patients treated with CRT during the course of RT was
Table 1 Characteristics of IMRT and CRT patients
Characteristic IMRT CRT P value
Patient number 65 69 0,53*
Age (y)
Median 62 64 0.75*
Range 35 – 96 28 – 88
Tumor site
Endometrium 17 (26.1%) 20 (29%)
Cervix 8 (12.3%) 3 (4.3%) <0.001
Rectum 21 (32.3%) 40 (58%)
Anal Canal 7 (10.8%) 6 (8.7%)
Bladder 12 (18.5%) 0
RT goal
Adjuvant 29 39 0.004
Neo-adjuvant 14 23
Definitive 22 7
Gender
Female 44 39 0.18
Male 21 30
Chemotherapy 0.42
Yes 39 46
No 26 23
* Student t test
Table 2 Dose volume restrictions for pelvic OARs used in
Hospital Israelita Albert Einstein
OAR DOSE VOLUME RESTRICTIONS
RECTUM ≤ 55%: ≥ 47 Gy ≤ 40%: ≥ 65 Gy
≤ 25%: ≥ 70 Gy ≤ 10%: ≥ 75 Gy
Dmax: 82 Gy
SMALL BOWEL ≤ 100%: ≥ 40 Gy ≤ 66%: ≥ 45 Gy
≤ 33%: ≥ 50 Gy
Dmax: 60 Gy
BLADDER ≤ 55%: ≥ 47 Gy ≤ 30%: ≥ 70 Gy
Dmax: 82 Gy
FEMORAL HEAD Dmax: 50 Gy
Dmax: Maximum point dose.
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trium cancer was treated with CT, patients with cervix
cancer, when treated with concomitant CT and RT,
received weekly Cisplatin (40 mg/m
2). Those with rectal
cancer received oral daily Capecitabine (825 mg/m
2
BID, 5 days/week), those with anal canal cancer received
5-Flourouracil (1000 mg/m
2 continuous infusion days 1
- 4) and Mitomycin-C (10 mg/m
2 on day 1) during the
first and last week of RT, and those with bladder cancer
received weekly Cisplatin (40 mg/m
2).
In the CRT group the proportion of patients who
underwent CT according to the primary tumor site was:
endometrium: 0/20 (0%); cervix: 1/3 (33%); rectum: 39/
40 (98%) and anal canal: 6/6 (100%), while in the IMRT
group the proportion was: endometrium: 0/17 (0%); cer-
vix: 4/8 (50%); rectum: 18/21 (86%); anal canal: 7/7
(100%) and bladder: 9/11 (82%).
Analysis of Acute toxicity
All patients were evaluated weekly for acute GI and GU
toxicities during the RT. Symptoms and treatment were
recorded on the chart. We retrospectively reviewed
these charts and graded acute GI and GU toxicities by
the RTOG/EORTC acute radiation morbidity criteria
[27]. Patients with rectal cancer were analyzed
separately.
Statistical analysis
All statistical analyses were performed with a statistical
software STATA Statistics/Data analysis (STATA Corp.
2001 Stata Statistical Software: Release 7.0 College Sta-
tion, TX: Stata Corporation). The primary endpoints to
be compared between both groups were incidence and
severity of acute GI and GU toxicities during RT. The
Chi-square frequencies test was used to verify the asso-
ciation between categorical variables and contingency
tables. The Fisher’s exact test was adopted in tables 2 ×
2 when at least one expected frequency was lower than
5. The Student’s t test was applied to verify association
of numerical variables between the CRT and IMRT
groups. A 5% significance level was considered for all
statistical analyses.
Results
The characteristics of CRT and IMRT patients are sum-
marized in Table 1. All but tumor site distribution and
RT goal are equally balanced in both groups.
The crude incidence of grade 2 acute GI (medication
for diarrhea) was more frequent in the CRT group
(65,2% Vs 38,5%; p < 0.001) and absence of any GI
symptoms (grade 0) was more frequently observed
among patients treated with the IMRT technique (82.4%
Vs 17.6%; p < 0.001). Table 3 shows the crude incidence
of acute GI toxicity according to RTOG/EORTC grading
criteria.
The crude incidence of acute GU complications was
statistically similar in bothg r o u p s( T a b l e4 ) .U r i n a r y
symptoms not requiring medication (grade 1) were mar-
ginally more frequent among patients treated with
IMRT (20% Vs 8.7%, p = 0.06).
Patients with rectal cancer treated with IMRT pre-
sented a lower incidence of acute grade 2 (medication
for diarrhea) GI toxicities (9.5% Vs 65%; p <0 . 0 1 ) .
Absence of any symptom (grade 0) was more frequently
found in patients treated with IMRT (23.8% Vs 5%; p =
0.077). Acute grade 1 GI toxicity was more frequent in
patients from the IMRT group (66.6% Vs 20%; p < 0.01)
(Table 5). Crude incidence of acute GU toxicity was
similar in both groups among patients with rectal cancer
(Table 6).
Discussion
Use of IMRT in the treatment of pelvic tumors has been
increasing throughout the world for more than a decade.
Our results of acute toxicity among patients in the
IMRT group were presented at the 2009 Annual
ASTRO meeting [28]. Many publications discuss the
theoretical advantages of IMRT dose distribution and
two complete revisions about its use in gynecological
cancers have already been published [29,30]. Further-
more, there are several dosimetric studies that show
reduction of dose delivered to the pelvic OARs with
IMRT when compared with conventional or CRT tech-
niques in the treatment of gynecological cancers
[6-8,10,14,15], rectal cancer [5,11], anal canal cancer
[9,13] and bladder cancer [12]. However, the main
Table 3 Crude incidence of acute GI toxicity in both
groups according to RTOG/EORTC acute radiation
morbidity criteria
Grade IMRT group (n = 65) CRT group (n = 69) P value
0 28 (43.1%) 6 (8.7%) <0.001
1 12 (18.5%) 13 (18.8%) 0.955
2 25 (38.5%) 45 (65.2%) 0.002
3 0 (0%) 5 (7.2%) 0.058*
*Fisher’s exact test
Table 4 Crude incidence of acute GU toxicity in both
groups according to RTOG/EORTC acute radiation
morbidity criteria
Grade IMRT group (n = 65) CRT group (n = 69) P value
0 40 (61.5%) 46 (66.6%) 0.54
1 13 (20%) 6 (8.7%) 0.06
2 12 (18.5%) 16 (23.5%) 0.50
3 0 (0%) 1 (1.5%) >0.99*
*Fisher’s exact test
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can lead to clinically relevant results when compared
with non-modulated external beam RT.
Veldeman et al [31] made a systematic review of 41
comparative clinical studies with the use of IMRT that
reported on overall survival, disease-specific survival,
quality of life and/or treatment-induced toxicity, pub-
lished prior to August 21, 2007. Concerning pelvic
tumors, the authors did not find any prospective study
that compares IMRT with non-IMRT technique.
Furthermore, no study about overall survival, disease-
specific survival or quality of life had been published
until then. These authors identified three comparative
case series for gynecological malignancies that signifi-
cantly showed lower rates of acute GI toxicity
[16,17,24], one with less chronic GI toxicity [18], one
with less hematological side effects [23] and one with
lower acute GU toxicities [24] in patients treated by pel-
vic IMRT in comparison to those treated by non-IMRT
techniques. For anal canal cancer, they included just one
non-comparative case series with 17 patients that
showed no grade 3 or higher acute non-hematological
toxic effects or treatment breaks attributable to GI or
skin toxicity [9].
Other clinical studies have also been published about
use of IMRT in gynecological cancers [19,20,22], and
[25], in rectal cancer [21] and in bladder cancer [12]. All
these studies showed a lower rate of radiation-induction
toxicity with IMRT.
Considering evidence-based medicine, multi-institu-
tional prospective clinical trials are important to corro-
borate the real benefit of IMRT in the treatment of
pelvic tumors. The Radiation Therapy Oncology Group
(RTOG) is conducting a prospective phase II study of
IMRT for postoperative patients with either endometrial
or cervical carcinoma with or without chemotherapy
(RTOG 0418) and the Tata Memorial Hospital, in
Mumbai, India, is conducting the only ongoing prospec-
tive phase II randomized trial comparing conventional
RT versus IMRT in the treatment of cervical cancer.
Results of these two trials will contribute to assess the
benefits and risks of IMRT in patients with gynecologic
tumors.
The most important result from our series was the
lower incidence of medication for diarrhea (grade 2)
among patients treated with IMRT. Diarrhea is a very
uncomfortable symptom and can cause dehydration and
malabsorption of vitamins, lactose, and bile acids [4].
Another important finding was the higher absence of GI
symptoms (grade 0) in IMRT group (43.1% versus 8.7%;
p < 0.001). The possibility of offering a greater opportu-
nity to avoid GI symptoms to patients under RT treat-
ment is a considerable advantage for IMRT. Because use
of CT is now well established for treatment of some pel-
vic tumors sites, such as the rectum, cervix, anal canal
and bladder, IMRT can be very useful to reduce the
acute toxicities potentialized by CT since it not only
improves delivery of CT but also potentially provides
conditions for CT dose escalation.
In our series, use of IMRT did not reduce acute GU
toxicities. The incidence of acute grade 1 GU side
effects was marginally more frequent in the IMRT
group (20% versus 8.7%; p = 0.06) as shown in table 4.
As grade 1 acute GU radiation morbidity is defined by
RTOG/EORTC criteria as “Frequency of urination or
nocturia twice pretreatment habit and dysuria or
urgency not requiring medication” [27], this difference is
not important in clinical practice and definition of this
grade could be subjective, as the information collected
was based on physician’s notes in patient’s charts.
Our results of lower acute GI toxicity in the IMRT
group and similar acute GU toxicity in both groups
were like those reported by the Mundt et al. [17]
through a comparative case series for women with gyne-
cological malignancies. They reported on grade 2 acute
GI toxicity less common in the IMRT group than in the
conventional RT (60% vs. 91%; p =0 . 0 0 2 )a n dg r a d e2
GU toxicity not statistically significant (10% vs. 20%; p =
0.22).
Due to the relatively greater number of patients with
rectal cancer in the CRT group and that almost all had
been treated by combined CT with capecitabine (98% in
t h eC R Tg r o u pa n d8 6 %i nt h eI M R Tg r o u p ) ,w ep e r -
formed a separate analysis of these patients. Absence of
GI symptoms (grade 0) was greater in IMRT group
(23.8% versus 5%; p =0 . 0 7 ) ,a ss h o w ni nt a b l e5 .
Table 5 Crude incidence of acute GI toxicity in both
groups according to RTOG/EORTC acute radiation
morbidity criteria in patients with rectal cancer
Grade IMRT group (n = 21) CRT group (n = 40) P value
0 5 (23.8%) 2 (5%) 0.077
1 14 (66.6%) 8 (20%) <0.001
2 2 (9.5%) 26 (65%) <0.001
3 0 (0%) 4 (10%) 0.339*
*Fisher’s exact test
Table 6 Crude incidence of acute GU toxicity in both
groups according to RTOG/EORTC acute radiation
morbidity criteria in patients with rectal cancer
Grade IMRT group (n = 21) CRT group (n = 40) P value
0 18 (85.7%) 26 (65%) 0.086
1 2 (9.5%) 4 (10%) 0.694
2 1 (4.8%) 9 (22.5%) 0.157
3 0 (0%) 1 (1.5%) > 0.99*
*Fisher’s exact test
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in the IMRT group (9.5% versus 65%; p < 0.001). Con-
sidering that capecitabine alone can also cause diarrhea
and increase radiosensitivity, this finding is considerably
positive in favor of IMRT. Curiously, grade 1 acute GI
toxicity was more often found among patients treated
by IMRT. Because grade 1 acute GI side effects are
described by RTOG/EORTC criteria as “increased fre-
quency or change in quality of bowel habits nor requir-
ing medication or rectal discomfort not requiring
analgesics” [27], this finding is not relevant in the clini-
cal practice and these symptoms are a subjective
endpoint.
No difference was observed in crude incidence of
acute GU toxicity in patients with rectal cancer treated
with CRT or IMRT technique (Table 6) as we also
observed when all patients with other primary tumor
sites are considered (Table 4). These findings suggest
that the bladder is less sensitive to reductions in volume
irradiated than the small bowel, especially when the
total dose is up to 50 Gy. We also must consider that
the low number of events could have limited the statisti-
cal power of this analysis.
Another advantage of IMRT is the possibility to deli-
ver a different level of daily dose to the distinct target
volumes. In our Institution, we routinely treat patients
with rectal cancer with preoperative RT concomitant
to CT and due to the lesser probability of small bowel
toxicity with IMRT, all patients are nowadays treated
with this technique using synchronous integrated boost
(SIB) strategy to deliver 50 Gy (2 Gy/fraction) to the
gross primary tumor while simultaneously delivering
45 Gy (1.8 Gy/fraction) to the regional lymph nodes
and areas of risk for harboring microscopic disease
( F i g u r e1 ) .T h e r ei so n eo n g o i n gp r o s p e c t i v ef a s eI I
trial using preoperative SIB-IMRT strategy and capeci-
tabine for treatment of locally advanced rectal cancer
[21]. In this study, a total dose of 55 Gy (2.2 Gy/frac-
tions) is delivered to the primary tumor and of 45 Gy
(1.8 Gy/fractions) to the lymph nodes regions in 25
fractions. The preliminary results already published,
with only eight patients showed an impressive patholo-
gic complete response rate of 38% with minimal toxi-
city. These results warrant further evaluation in future
larger cooperative and prospective phase II or phase III
trials.
In conclusion, this retrospective and comparative case
series showed that use of the IMRT technique to treat
pelvic tumors reduced the frequency and severity of GI
symptoms and the need of medication for diarrhea in
comparison to the CRT technique, but did not reduce
incidence of acute GU toxicities. For rectal cancer
patients these benefits were also observed, even with
concomitant CT. For these reasons, the IMRT techni-
que, when available, should be considered to treat pelvic
tumors whenever the lymph nodes and primary tumor
sites must be irradiated.
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Figure 1 Dose distributions with SIB-IMRT strategy at lymph node regions and primary tumor site in a patient with low rectal cancer,
to receive 45 Gy (blue painting) and 50 Gy (orange painting), respectively, in 25 daily fractions.
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